Emergent BioSolutions (EBS) Accumulated Expenses (2010 - 2026)

Emergent BioSolutions' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $22.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 10.93% year-over-year to $22.0 million in Q1 2026; TTM through Mar 2026 was $22.0 million, a 10.93% decrease from a year earlier, with the FY2025 full-year figure at $41.8 million, down 25.49% from the prior year.
• Accumulated Expenses fell to $22.0 million in Q1 2026 per EBS's latest filing, from $41.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $74.4 million in Q2 2022 and bottomed at $13.6 million in Q2 2025.
• The 5-year median for Accumulated Expenses is $31.2 million (2023), against an average of $35.3 million.
• Across the five-year window, Accumulated Expenses soared 112.32% in 2023 and sank 74.82% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $34.9 million in 2022, then surged by 112.32% to $74.1 million in 2023, then decreased by 24.29% to $56.1 million in 2024, then decreased by 25.49% to $41.8 million in 2025, then sank by 47.37% to $22.0 million in 2026.
• Per Business Quant, the three latest EBS Accumulated Expenses figures stand at $22.0 million (Q1 2026), $41.8 million (Q4 2025), and $13.9 million (Q3 2025).